Published in PLoS One on December 11, 2013
Neuroblastoma tyrosine kinase signaling networks involve FYN and LYN in endosomes and lipid rafts. PLoS Comput Biol (2015) 0.82
TRPM7 maintains progenitor-like features of neuroblastoma cells: implications for metastasis formation. Oncotarget (2015) 0.80
Novel multiple tyrosine kinase inhibitor ponatinib inhibits bFGF-activated signaling in neuroblastoma cells and suppresses neuroblastoma growth in vivo. Oncotarget (2016) 0.80
N-linked glycan profiling in neuroblastoma cell lines. J Proteome Res (2015) 0.76
HIPK2-T566 autophosphorylation diversely contributes to UV- and doxorubicin-induced HIPK2 activation. Oncotarget (2017) 0.75
Posttranslational modifications of neuroligins regulate neuronal and glial signaling. Curr Opin Neurobiol (2017) 0.75
Statistical significance for genomewide studies. Proc Natl Acad Sci U S A (2003) 88.64
Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis (1999) 45.01
The protein kinase complement of the human genome. Science (2002) 35.36
Untangling the ErbB signalling network. Nat Rev Mol Cell Biol (2001) 28.05
Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. Nat Methods (2007) 25.29
PANTHER: a library of protein families and subfamilies indexed by function. Genome Res (2003) 21.64
Oncogenic kinase signalling. Nature (2001) 16.30
The PANTHER database of protein families, subfamilies, functions and pathways. Nucleic Acids Res (2005) 13.37
A probability-based approach for high-throughput protein phosphorylation analysis and site localization. Nat Biotechnol (2006) 12.13
Signaling--2000 and beyond. Cell (2000) 11.78
Neuroblastoma. Lancet (2007) 10.61
Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science (1994) 10.45
Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell (1995) 8.75
Recent advances in neuroblastoma. N Engl J Med (2010) 7.86
Identification of ALK as a major familial neuroblastoma predisposition gene. Nature (2008) 7.38
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta (2006) 7.33
Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature (2008) 6.80
Quantitative mass spectrometry in proteomics: a critical review. Anal Bioanal Chem (2007) 6.80
Differential regulation and properties of MAPKs. Oncogene (2007) 6.36
Regulation of Raf-1 by direct feedback phosphorylation. Mol Cell (2005) 5.88
Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature (1993) 5.81
Oncogenic mutations of ALK kinase in neuroblastoma. Nature (2008) 5.80
Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature (1987) 5.46
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature (2008) 5.32
Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med (2000) 5.04
The genetic landscape of high-risk neuroblastoma. Nat Genet (2013) 4.71
Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature (2012) 4.53
Sonic hedgehog regulates adult neural progenitor proliferation in vitro and in vivo. Nat Neurosci (2003) 3.98
The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J Biol Chem (2003) 3.83
Decoding signalling networks by mass spectrometry-based proteomics. Nat Rev Mol Cell Biol (2010) 3.78
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol (2013) 3.70
Targeting tyrosine kinases in cancer: the second wave. Science (2006) 3.52
Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat Genet (2012) 3.38
Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol (2009) 3.07
The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol (2008) 2.94
JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia (2004) 2.76
Phosphorylation of Ser-241 is essential for the activity of 3-phosphoinositide-dependent protein kinase-1: identification of five sites of phosphorylation in vivo. Biochem J (1999) 2.74
The IGF-1 receptor in cancer biology. Int J Cancer (2003) 2.66
Mechanisms of regulating the Raf kinase family. Cell Signal (2003) 2.58
Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy. Cancer Lett (2008) 2.57
Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA (2012) 2.49
Human Protein Reference Database and Human Proteinpedia as discovery tools for systems biology. Methods Mol Biol (2009) 2.47
Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. FASEB J (2002) 2.25
Neuroblastoma: biology, prognosis, and treatment. Hematol Oncol Clin North Am (2010) 2.21
Integrative genomics identifies LMO1 as a neuroblastoma oncogene. Nature (2010) 2.21
Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene (2009) 2.17
Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. Cancer Chemother Pharmacol (2013) 2.09
Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. Am J Hum Genet (2004) 1.98
Contrasting effects of IRS-1 versus IRS-2 gene disruption on carbohydrate and lipid metabolism in vivo. J Biol Chem (2000) 1.95
RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. Proc Natl Acad Sci U S A (2011) 1.90
Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma. Sci Transl Med (2012) 1.89
Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene (2002) 1.87
Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Res (2002) 1.84
NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell (2010) 1.81
Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer. Mol Cancer Ther (2010) 1.70
Profiling of tyrosine phosphorylation pathways in human cells using mass spectrometry. Proc Natl Acad Sci U S A (2003) 1.68
Structural basis for activation and inhibition of class I phosphoinositide 3-kinases. Sci Signal (2011) 1.68
BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. Mol Cancer Ther (2009) 1.62
FGF receptors: cancer biology and therapeutics. Med Res Rev (2013) 1.59
Phenotype restricted genome-wide association study using a gene-centric approach identifies three low-risk neuroblastoma susceptibility Loci. PLoS Genet (2011) 1.57
Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Oncologist (2009) 1.53
Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium. Mol Cancer Ther (2008) 1.47
Prognostic impact of gene expression-based classification for neuroblastoma. J Clin Oncol (2010) 1.43
The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr Pharm Des (2007) 1.43
SIRT1 promotes N-Myc oncogenesis through a positive feedback loop involving the effects of MKP3 and ERK on N-Myc protein stability. PLoS Genet (2011) 1.41
Neuroblastoma: Therapeutic strategies for a clinical enigma. Cancer Treat Rev (2010) 1.38
Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo. Oncogene (2007) 1.36
Targeting RET receptor tyrosine kinase activation in cancer. Clin Cancer Res (2010) 1.32
Protein phosphatase 2A reactivates FOXO3a through a dynamic interplay with 14-3-3 and AKT. Mol Biol Cell (2010) 1.29
Charging it up: global analysis of protein phosphorylation. Trends Genet (2006) 1.29
Biological effects of TrkA and TrkB receptor signaling in neuroblastoma. Cancer Lett (2005) 1.28
A new approach for quantitative phosphoproteomic dissection of signaling pathways applied to T cell receptor activation. Mol Cell Proteomics (2009) 1.25
Combination therapy targeting the Chk1 and Wee1 kinases shows therapeutic efficacy in neuroblastoma. Cancer Res (2012) 1.25
mTOR-dependent cell survival mechanisms. Cold Spring Harb Perspect Biol (2012) 1.24
Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer (2010) 1.24
Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies. Paediatr Drugs (2012) 1.22
Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors. J Clin Oncol (2011) 1.18
Quantitative time-resolved phosphoproteomic analysis of mast cell signaling. J Immunol (2007) 1.16
Activation of IRS-2-mediated signal transduction by IGF-1, but not TGF-alpha or EGF, augments pancreatic beta-cell proliferation. Diabetes (2002) 1.14
Phosphatidylinositol 3-kinase: the oncoprotein. Curr Top Microbiol Immunol (2010) 1.14
Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma. Br J Cancer (2009) 1.08
Insulin-like growth factor-I receptor expression regulates neuroblastoma metastasis to bone. Cancer Res (2006) 1.07
Targeting the PI3K/AKT/mTOR pathway: biomarkers of success and tribulation. Am Soc Clin Oncol Educ Book (2013) 1.06
The neuron-specific Rai (ShcC) adaptor protein inhibits apoptosis by coupling Ret to the phosphatidylinositol 3-kinase/Akt signaling pathway. Mol Cell Biol (2002) 1.06
FAK inhibition decreases cell invasion, migration and metastasis in MYCN amplified neuroblastoma. Clin Exp Metastasis (2012) 1.05
Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo. Clin Cancer Res (2006) 1.04
The PI3K/Akt/mTOR pathway as therapeutic target in neuroblastoma. Curr Cancer Drug Targets (2009) 1.04
Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer. Cancer Res (2011) 1.04
New strategies in refractory and recurrent neuroblastoma: translational opportunities to impact patient outcome. Clin Cancer Res (2012) 1.04
Specific expression of the ret proto-oncogene in human neuroblastoma cell lines. Oncogene (1990) 1.04
Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma. Clin Cancer Res (2013) 1.03
A solid phase extraction-based platform for rapid phosphoproteomic analysis. Methods (2011) 1.02
Global genomic and proteomic analysis identifies biological pathways related to high-risk neuroblastoma. J Proteome Res (2010) 1.00
Truncated trkB.T1 is dominant negative inhibitor of trkB.TK+-mediated cell survival. Biochem Biophys Res Commun (2001) 1.00
PeptideDepot: flexible relational database for visual analysis of quantitative proteomic data and integration of existing protein information. Proteomics (2009) 0.99
BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer. Mol Cancer Ther (2012) 0.99
Insulin-like growth factor-I signaling in human neuroblastoma cells. Oncogene (2004) 0.99
N-Myc induction stimulated by insulin-like growth factor I through mitogen-activated protein kinase signaling pathway in human neuroblastoma cells. Cancer Res (2000) 0.98
Mouse 3-phosphoinositide-dependent protein kinase-1 undergoes dimerization and trans-phosphorylation in the activation loop. J Biol Chem (2003) 0.98
Phosphoproteomic profiling of in vivo signaling in liver by the mammalian target of rapamycin complex 1 (mTORC1). PLoS One (2011) 0.98